Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Aptevo Therapeutics Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −1 vs. Q3 2025
- Shares held
- 20.3K
- −7.15K (−26.0%) vs. Q3 2025Converted for a 1-for-18 split
- Total value
- $191.4K
- −$525.8K (−73.3%) vs. Q3 2025
- New holders
- 4
- 4 more added
- Sold out
- 5
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 16,856 | $159.0K | 0.00% | +16,856 | New |
| Citigroup Inc | 2,756 | $26.0K | 0.00% | +2,752+66,937.8% | AddedConverted for a 1-for-18 split |
| Advisor Group Holdings, Inc. | 360 | $3.39K | 0.00% | 00.0% | UnchangedConverted for a 1-for-18 split |
| UBS Group AG | 170 | $1.60K | 0.00% | −145−46.1% | ReducedConverted for a 1-for-18 split |
| Tower Research Capital LLC (TRC) | 92 | $868 | 0.00% | +12+14.6% | AddedConverted for a 1-for-18 split |
| SBI Securities Co., Ltd. | 31 | $292 | 0.00% | −1−2.1% | ReducedConverted for a 1-for-18 split |
| Tradewinds Capital Management, LLC | 13 | $118 | 0.00% | +13 | New |
| Bank of America Corp | 7 | $66 | 0.00% | +5+366.7% | AddedConverted for a 1-for-18 split |
| FMR LLC | 7 | $66 | 0.00% | +7 | New |
| Danske Bank A/S | 1 | $9 | 0.00% | +1+1,700.0% | AddedConverted for a 1-for-18 split |
| CWM, LLC | 6 | $0 | 0.00% | +6 | New |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −16,664−100.0% | Sold outConverted for a 1-for-18 split |
| DRW Securities, LLC | 0 | $0 | 0.00% | −7,304−100.0% | Sold outConverted for a 1-for-18 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −2,127−100.0% | Sold outConverted for a 1-for-18 split |
| Colony Group, LLC | 0 | $0 | 0.00% | −556−100.0% | Sold outConverted for a 1-for-18 split |
| BlackRock, Inc. | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-18 split |